Bharat Biotech has sought permission from Drugs Controller General of India (DCGI) to conduct a phase 2/3 study of its anti-COVID vaccine Covaxin as a booster dose among those aged two to 17 years, sources told PTI.

Presently, precaution dose of Covaxin and Covishield is administered to all those aged 18 and above, and have completed nine months after the second dose.